<P><A href=javascript:AddCoCode(4684,'NATCO PHARM','Natco Pharma ')><FONT color=black>Natco Pharma</FONT></A>&nbsp;announced the launch of Bosentan tablets for oral suspension (TFOS), 32mg, a generic version of Tracleer® by Actelion Pharmaceuticals US Inc. NATCO's marketing partner for the product is Lupin. </P> <P>Natco holds the first-to-file status for this product and will have 180-day generic drug exclusivity. They are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in paediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability. </P> <P>Bosentan tablets for oral suspension (TFOS), 32mg had estimated sales of USD 10 million in the U.S. for 12 months ending June'25 as per industry sales data. </P>